Press Release Details

Cerus Announces Mississippi Valley Regional Blood Center Enters Into Agreement for the Use of INTERCEPT Platelets and Plasma

December, 04 2015

CONCORD, Calif. & DAVENPORT, Iowa--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that the Mississippi Valley Regional Blood Center (MVRBC) has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma.

“With support from our donors, we provide world class blood and blood components to hospitals throughout our region,” said Mike Parejko, MVRBC’s Chief Executive Officer. “We do so with an unwavering focus on the quality and safety of our products. INTERCEPT-treated platelets and plasma will enable us to offer another safe choice of blood components to the hospitals we serve.”

The Mississippi Valley Regional Blood Center is the exclusive provider of blood products and services to 88 hospitals in Illinois, Iowa, Missouri, and Wisconsin. MVRBC is headquartered in Davenport, Iowa, where its testing, processing, and primary distribution center handles more than 400,000 units of blood components annually. The population of MVRBC’s service region exceeds 4 million residents, and donors give more than 200,000 donations each year.


Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See for more information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation

Stacey Leanos - Associate Director, Investor & Public Relations

Lainie Corten - Vice President, Global Marketing & Investor Relations



Mississippi Valley Regional Blood Center

Kirby Winn, 563-359-5401

Director of Public Relations

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600